IP Library Granted Patent US 9,708,635
Granted Patent B2
US 9,708,635 · App. 13/719,819 · Granted Jul 18, 2017

Methods of making a nucleic acid encoding a human variable region

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,708,635
App. No.
13/719,819
Granted
Jul 18, 2017
Kind
B2
Abstract

A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.

Claims (17)

1. A method of producing a nucleic acid encoding a human immunoglobulin heavy chain variable region, the method comprising:

(a) providing a transgenic mouse whose genome comprises in its germline unrearranged human immunoglobulin heavy chain V, D, and J gene segments, wherein the unrearranged human immunoglobulin heavy chain V, D, and J gene segments in situ replace endogenous mouse immunoglobulin heavy chain V, D, and J gene segments, and the unrearranged human immunoglobulin heavy chain V, D, and J gene segments are operably linked to an endogenous mouse heavy chain constant region gene, wherein the mouse heavy chain constant region gene is located at an endogenous mouse immunoglobulin heavy chain constant region locus, wherein rearrangement of the unrearranged human immunoglobulin heavy chain V, D, and J gene segments in the mouse results in a rearranged immunoglobulin human heavy chain variable region gene linked to the mouse heavy chain constant region gene, wherein the mouse in response to an antigen produces a hybrid antibody that comprises a human immunoglobulin heavy chain variable region encoded by the rearranged human immunoglobulin heavy chain variable region gene and a mouse heavy chain constant region encoded by the mouse heavy chain constant region gene;

(b) stimulating an immune response in the mouse by exposing the mouse to an antigen;

(c) preparing a hybridoma expressing the hybrid antibody from the spleen of the mouse stimulated by the antigen in step (b); and

(d) isolating DNA encoding the human immunoglobulin heavy chain variable region of the hybrid antibody from the hybridoma of step (c).

2. The method of claim 1 , wherein mouse V gene segments are present upstream of the unrearranged human immunoglobulin heavy chain V, D, and J gene segments.

3. The method of claim 1 , wherein the endogenous immunoglobulin enhancer Eμ remains intact upstream of the mouse heavy chain constant region gene.

4. The method of claim 3 , wherein mouse V gene segments are present upstream of the unrearranged human immunoglobulin heavy chain V, D, and J gene segments.

5. The method of claim 1 , wherein the DNA encoding the human immunoglobulin heavy chain variable region of the antibody is isolated in step (d) by PCR amplification or cDNA cloning.

6. A method of producing a nucleic acid encoding a human immunoglobulin heavy chain variable region, the method comprising:

(a) providing a transgenic mouse whose genome comprises in its germline unrearranged human immunoglobulin heavy chain V, D, and J gene segments, wherein the unrearranged human immunoglobulin heavy chain V, D, and J gene segments in situ replace endogenous mouse immunoglobulin heavy chain V, D, and J gene segments, and the unrearranged human immunoglobulin heavy chain V, D, and J gene segments are operably linked to an endogenous mouse heavy chain constant region gene, wherein the mouse heavy chain constant region gene is located at an endogenous mouse immunoglobulin heavy chain constant region locus, wherein rearrangement of the unrearranged human immunoglobulin heavy chain V, D, and J gene segments in the mouse results in a rearranged human immunoglobulin heavy chain gene linked to the mouse heavy chain constant region gene, wherein the mouse in response to an antigen produces a hybrid antibody that comprises a human immunoglobulin heavy chain variable region encoded by the rearranged human immunoglobulin heavy chain variable region gene and a mouse heavy chain constant region encoded by the mouse heavy chain constant region gene;

(b) stimulating an immune response in the mouse by exposing the mouse to an antigen; and

(c) isolating DNA encoding the human immunoglobulin heavy chain variable region of the hybrid antibody from the mouse stimulated by with the antigen in step (b).

7. The method of claim 6 , wherein mouse V gene segments are present upstream of the unrearranged human immunoglobulin heavy chain V, D, and J gene segments.

8. The method of claim 6 , wherein the endogenous immunoglobulin enhancer Eμ remains intact upstream of the mouse heavy chain constant region gene.

9. The method of claim 8 , wherein mouse V gene segments are present upstream of the unrearranged human heavy chain V, D, and J gene segments.

10. The method of claim 6 , wherein the DNA encoding the human heavy chain variable region of the antibody is isolated in step (c) by PCR amplification or cDNA cloning.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2014
From: ECONOMIDES, ARIS N.; VALENZUELA, DAVID M.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 032738/0571 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2013
From: KAROW, MARGARET; MACDONALD, LYNN; STEVENS, SEAN
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 031100/0121 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2013
From: MURPHY, ANDREW J.; YANCOPOULOS, GEORGE D.
To: REGENERON PHARMACEUTICALS INC.
Reel/Frame 030068/0356 →